Board approved unaudited Q4 FY26 results with revenue of ₹4,723 million and net profit of ₹1,026 million.
Independent Directors Aditya Narayan and Usha Thorat completed their tenure effective April 29, 2026.
Rahul Bhatnagar appointed as Chairman and all board committees were reconstituted effective April 30, 2026.
Management highlighted 19% YoY growth in insulin portfolio but noted overall results impacted by partnership transitions.